U.S. OKs Glaxo Drug for Seasonal Depression

London-based GlaxoSmithKline won U.S. approval to market its antidepressant Wellbutrin XL to patients with seasonal affective disorder, the Food and Drug Administration said.

The FDA said Wellbutrin XL was the first drug approved for patients with the disorder, which causes episodes of depression that coincide with seasonal decreases of daylight.